| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018 | 463 | 2018 |
| Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis KM Hallow, Y Gebremichael, G Helmlinger, V Vallon American Journal of Physiology-Renal Physiology 312 (5), F819-F835, 2017 | 98 | 2017 |
| A tutorial on RxODE: simulating differential equation pharmacometric models in R W Wang, KM Hallow, DA James CPT: pharmacometrics & systems pharmacology 5 (1), 3-10, 2016 | 85 | 2016 |
| A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model KM Hallow, A Lo, J Beh, M Rodrigo, S Ermakov, S Friedman, H de Leon, ... American Journal of Physiology-Regulatory, Integrative and Comparative …, 2014 | 68 | 2014 |
| Influence of cytoskeletal structure and mechanics on epithelial cell injury during cyclic airway reopening HC Yalcin, KM Hallow, J Wang, MT Wei, HD Ou-Yang, SN Ghadiali American Journal of Physiology-Lung Cellular and Molecular Physiology 297 (5 …, 2009 | 64 | 2009 |
| Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018 | 58 | 2018 |
| A quantitative systems physiology model of renal function and blood pressure regulation: model description KM Hallow, Y Gebremichael CPT: Pharmacometrics & Systems Pharmacology 6 (6), 383-392, 2017 | 47 | 2017 |
| Quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ... CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019 | 45 | 2019 |
| Model‐based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin JA Brady, KM Hallow The Journal of Clinical Pharmacology 58 (3), 377-385, 2018 | 30 | 2018 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 26 | 2017 |
| A quantitative systems physiology model of renal function and blood pressure regulation: application in salt‐sensitive hypertension KM Hallow, Y Gebremichael CPT: Pharmacometrics & Systems Pharmacology 6 (6), 393-400, 2017 | 25 | 2017 |
| Markers of inflammation collocate with increased wall stress in human coronary arterial plaque KM Hallow, WR Taylor, A Rachev, RP Vito Biomechanics and modeling in mechanobiology 8, 473-486, 2009 | 25 | 2009 |
| Multiscale mathematical model of drug-induced proximal tubule injury: linking urinary biomarkers to epithelial cell injury and renal dysfunction Y Gebremichael, J Lu, H Shankaran, G Helmlinger, J Mettetal, KM Hallow Toxicological Sciences 162 (1), 200-211, 2018 | 22 | 2018 |
| The adaptive renal response for volume homeostasis during 2 weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet RA Scholtes, MHA Muskiet, MJB van Baar, AC Hesp, PJ Greasley, ... Kidney International Reports 7 (5), 1084-1092, 2022 | 14 | 2022 |
| Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis H Yu, S Basu, KM Hallow PLoS computational biology 16 (8), e1008074, 2020 | 14 | 2020 |
| Predicted cardiac hemodynamic consequences of the renal actions of SGLT2i in the DAPA‐HF study population: a mathematical modeling analysis H Yu, W Tang, PJ Greasley, RC Penland, DW Boulton, KM Hallow The Journal of Clinical Pharmacology 61 (5), 636-648, 2021 | 11 | 2021 |
| Renal effects of dapagliflozin in people with and without diabetes with moderate or severe renal dysfunction: prospective modeling of an ongoing clinical trial KM Hallow, DW Boulton, RC Penland, G Helmlinger, EH Nieves, ... Journal of Pharmacology and Experimental Therapeutics 375 (1), 76-91, 2020 | 10 | 2020 |
| Exposure-response modeling of flow-mediated dilation provides an unbiased and informative measure of endothelial function CH Van Brackle, RA Harris, KM Hallow Journal of Applied Physiology 122 (5), 1292-1303, 2017 | 10 | 2017 |
| Cardiorenal systems modeling: left ventricular hypertrophy and differential effects of antihypertensive therapies on hypertrophy regression KM Hallow, CH Van Brackle, S Anjum, S Ermakov Frontiers in physiology 12, 679930, 2021 | 8 | 2021 |
| A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone E Maddah, KM Hallow Journal of Pharmacokinetics and Pharmacodynamics 49 (4), 471-486, 2022 | 6 | 2022 |
